Gupta-Ganguli, M., Cox, K., Means, B., Gerling, I
At the higher doses, results were very consistent: All participants lost at least 5% of their body weight Around 3 in 4 lost 15% or more With placebo, only around 1 in 4 lost 5% or more Phase 3 update (TRIUMPH-4, 68 weeks, topline results) In December 2025 , Eli Lilly shared early (topline) results from a larger phase 3 study (TRIUMPH-4)
The material is not approved for clinical, therapeutic, diagnostic, human, or veterinary use and should be handled only in qualified laboratory settings
Some patients have reported: Improved brain fog and mental clarity Enhanced mood and reduced symptoms of depression A Note on Professional Sports While BPC-157 is not currently approved for professional athletes and has led to sanctions in organizations like the Olympics, this does not take away from its potential therapeutic value for others
Wegovy does not affect serotonin pathways